ACO2 and fatty liver disease: Accordingly, SUA enhances lipogenesis by activating ATP-citrate lyase and inhibiting both mitochondrial aconitase activity and AMP-activated kinase (AMPK) phosphorylation, thus predisposing to hepatic steatosis.